Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Kepivance op - vejer risiciene til mindskelse af hyppigheden, varigheden og sværheden af oral mucositis hos patienter med hæmatologiske maligniteter, som får myeloablativ behandling forbundet med en høj forekomst af svær mucositis og kræver autolog stamcelletransplantation.
The Committee for Medicinal products for Human Use (CHMP) decided that Kepivance’ s benefits are greater than its risks when used to decrease the incidence, duration and severity of oral mucositis in patients with haematological malignancies receiving myeloablative therapy associated with a high incidence of severe mucositis and requiring autologous stem cell support.